What Your Peers Think...

"In today's pharmaceutical environment two themes predominate, patient safety and probability of technical success. As development of new pharmaceuticals becomes more and more time consuming and expensive, any and all approaches which can identify potential problems must be explored. At the Predictive Toxicology Conference 2010, the aim is to provide attendees with practical knowledge which translates to better patient outcomes and better returns on investment"

'Late stage attrition of nascent drugs causes substantial losses, both financially and in terms of effort. Conversely, establishing assays with high false positive rates needlessly eliminates compounds that might well have been efficacious and safe in humans. De-risking strategies that predict clinical disposition are the ideal towards which we are moving; we need compounds to fail early, but for the right reasons. Recent advances on several fronts are providing in silico, cellular and animal models that more faithfully predict clinical reality. I am speaking at Predictive Toxicology again this year to help keep attention focused on mitochondrial dysfunction as a key safety issue, but also to hear about the latest developments on other fronts."